Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluate the Reactogenicity & Immunogenicity of 1 or 2 Booster Administrations of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults Aged Between 19 & 61 Years
Brief Summary: The present study is designed to evaluate the reactogenicity and immunogenicity of one or two booster administrations of an influenza pandemic candidate vaccine (GSK1562902A) in adults aged between 19 and 61 years, previously vaccinated with 2 doses of a pandemic candidate vaccine. Fifty new subjects who did not participate in a primary study (106750, NCT00309634) will be recruited. This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT00309634)


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Biological: VAX125 | Intervention Type: BIOLOGICAL; Name: VAX125; Assigned to Arm(s): A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Inactivated Split-virion influenza vaccine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Inactivated Split-virion influenza vaccine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: Inactivated Split-virion influenza vaccine | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Biological: Inactivated Split-virion influenza vaccine | Intervention Type: BIOLOGICAL; Name: Inactivated Split-virion influenza vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Inactivated Split-virion influenza vaccine; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Inactivated Split-virion influenza vaccine; Assigned to Arm(s): 3 | Intervention Type: BIOLOGICAL; Name: Inactivated Split-virion influenza vaccine; Assigned to Arm(s): 4
C: Arm Label: GSK1562902A non-AD F1 Primed Group; Type: EXPERIMENTAL; Interventions: Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses | Arm Label: GSK1562902A non-AD F2 Primed Group; Type: EXPERIMENTAL; Interventions: Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses | Arm Label: GSK1562902A non-AD F3 Primed Group; Type: EXPERIMENTAL; Interventions: Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses | Arm Label: GSK1562902A non-AD F4 Primed Group; Type: EXPERIMENTAL; Interventions: Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses | Arm Label: GSK1562902A AD F1 Primed Group; Type: EXPERIMENTAL; Interventions: Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose | Arm Label: GSK1562902A AD F2 Primed Group; Type: EXPERIMENTAL; Interventions: Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose | Arm Label: GSK1562902A AD F3 Primed Group; Type: EXPERIMENTAL; Interventions: Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose | Arm Label: GSK1562902A AD Approved F4 Primed Group; Type: EXPERIMENTAL; Interventions: Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose | Arm Label: Control Group; Type: EXPERIMENTAL; Interventions: Biological: Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses | Intervention Type: BIOLOGICAL; Name: Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose; Assigned to Arm(s): GSK1562902A AD Approved F4 Primed Group, GSK1562902A AD F1 Primed Group, GSK1562902A AD F2 Primed Group, GSK1562902A AD F3 Primed Group | Intervention Type: BIOLOGICAL; Name: Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses; Assigned to Arm(s): Control Group, GSK1562902A non-AD F1 Primed Group, GSK1562902A non-AD F2 Primed Group, GSK1562902A non-AD F3 Primed Group, GSK1562902A non-AD F4 Primed Group
D: Arm Label: VAX128; Type: EXPERIMENTAL; Interventions: Biological: VAX128 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: VAX128; Assigned to Arm(s): VAX128 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C